Valneva SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VALN | IVVD | IVACC.ST | NVAX | VIR | TVGN | |
|---|---|---|---|---|---|---|
| Market cap | 533.86M | 186.76M | 290.37M | 1.76B | 1.99B | 95.87M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 4.7 | -1.2 | -1.0 | -65.0 | -4.8 | — |
| Price/book | 5.9 | 1.0 | 1.2 | -9.2 | 2.1 | -1.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.78% | −61.71% | −6.91% | +25.88% | +107.78% | −77.45% |
| Today | +2.18% | +8.96% | −0.93% | +10.02% | +4.90% | −3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All VALN news ›Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company ...
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
The market withdrawal caps a tumultuous few years for the chikungunya vaccine amid related adverse events. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revoked approval for Valneva’s chikungunya vaccine after…
Valneva plans US and Europe healthcare investor talks
Valneva (VALN) expects decisions on its Pfizer-partnered Lyme vaccine candidate within 12 months Stock Titan Valneva plans US and Europe healthcare investor talks Valneva plans to discuss the partnered Lyme vaccine’s regulatory outlook,…
Valneva to present Lyme vaccine updates at US and European investor conferences
Valneva SE announced that its senior management will present and hold meetings with institutional investors at upcoming healthcare conferences in the US and Europe. The company will focus on discussing the regulatory outlook for its Lyme…
Bolloré, Exail, Kering, Valneva, Virbac... stocks to watch today in Paris
Published on 03/18/2026 at 04:04 am EDT Kering: Gaining traction, capped by industry headwinds October 08, 2026 at 06:10 am EDT Humana Lower on Profit Guidance; P&G Moves on Results | Stock Movers Kering bets on jewelry to revive growth
Valneva falls as UK revokes marketing authorization for chikungunya vaccine
Valneva stock drops after UK MHRA revokes Ixchiq chikungunya vaccine authorization over safety concerns. Read more here. Kitsawet Saethao/iStock via Getty Images - Valneva SE (VALN) is down ~5% in after-hours trading Wednesday after it…
Valneva’s IXCHIQ loses UK marketing authorization
A UK vaccine decision won't be appealed by Valneva (VALN), which expects minimal sales impact. Stock Titan Valneva’s IXCHIQ loses UK marketing authorization Valneva expects the UK revocation to have only minimal overall sales impact and no…
Valneva stock forecast: EMA validates Lyme vaccine application
As of 10:15am UTC on 16 September 2026, Valneva SE (VLA) traded at €2.86, within an intraday range of €2.79–€2.88. Past performance is not a reliable indicator of future results. Recent developments include the European Medicines Agency’s…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- capital.com1
- markets.financialcontent.com1
- marketscreener.com1
- pharmaceutical-technology.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.